Olyferic Injection contains Iron Sucrose 100mg, an intravenous iron preparation used primarily for the treatment of iron deficiency anemia, particularly in patients with chronic kidney disease (CKD) undergoing hemodialysis or those who are intolerant or unresponsive to oral iron therapy. Iron Sucrose serves as a vital component in hemoglobin synthesis and erythropoiesis by replenishing iron stores, thereby improving oxygen transport capacity. The injection is administered intravenously, allowing for rapid bioavailability and effective correction of iron deficiency. Olyferic is indicated for patients with documented iron deficiency anemia where oral iron is inadequate or contraindicated. The dosage and administration should be individualized based on the patient’s iron requirements, hemoglobin levels, and response to therapy, with careful monitoring to avoid iron overload. Common adverse effects may include hypotension, nausea, headache, and injection site reactions; serious hypersensitivity reactions are rare but require immediate medical attention. Olyferic Injection should be used with caution in patients with active infections or known hypersensitivity to iron preparations. It is contraindicated in patients with iron overload conditions such as hemochromatosis. Proper administration and monitoring ensure optimal therapeutic outcomes in managing iron deficiency anemia with Olyferic Injection.